LLY

1,074.85

+0.75%↑

JNJ

230.34

-1.8%↓

ABBV

212.12

-1.85%↓

UNH

380.23

-2.05%↓

AZN

187.05

-0.11%↓

LLY

1,074.85

+0.75%↑

JNJ

230.34

-1.8%↓

ABBV

212.12

-1.85%↓

UNH

380.23

-2.05%↓

AZN

187.05

-0.11%↓

LLY

1,074.85

+0.75%↑

JNJ

230.34

-1.8%↓

ABBV

212.12

-1.85%↓

UNH

380.23

-2.05%↓

AZN

187.05

-0.11%↓

LLY

1,074.85

+0.75%↑

JNJ

230.34

-1.8%↓

ABBV

212.12

-1.85%↓

UNH

380.23

-2.05%↓

AZN

187.05

-0.11%↓

LLY

1,074.85

+0.75%↑

JNJ

230.34

-1.8%↓

ABBV

212.12

-1.85%↓

UNH

380.23

-2.05%↓

AZN

187.05

-0.11%↓

Inicio・Lista de Acciones・Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals Inc

Abierto

SectorSanidad

89.57 2.52

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

87.37

Máximo

90.1

Métricas clave
By Trading Economics
Ingresos	-8.1M -56M
Ventas	2.9M 60M
BPA	-0.83
Margen de beneficios	-92.559
Empleados	414
EBITDA	-9.7M -52M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 Meses	+55.7% upside

Dividendos
By Dow Jones
Próximas Ganancias	4 ago 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	151M 6B
Apertura anterior	87.05
Cierre anterior	89.57

Noticias sobre sentimiento de mercado

By Acuity

50%

159 / 345 Clasificación en Healthcare

Rhythm Pharmaceuticals Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

25 may 2026, 08:24 UTC

Principales Movimientos del Mercado

Adquisiciones, fusiones, absorciones

Uber's $11.6 Billion Takeover Approach Lifts Delivery Hero Shares

25 may 2026, 21:22 UTC

Ganancias

Disney's 'Mandalorian and Grogu' Conquers Memorial Day Weekend Box Office -- Barrons.com

25 may 2026, 20:50 UTC

Charlas de Mercado

Ganancias

Basic Materials Roundup: Market Talk

25 may 2026, 16:20 UTC

Charlas de Mercado

Ganancias

Basic Materials Roundup: Market Talk

25 may 2026, 16:01 UTC

Charlas de Mercado

China's Crude Imports Pullback Helps Cap Price Upside -- Market Talk

25 may 2026, 14:43 UTC

Charlas de Mercado

Oil Unlikely to Fall Significantly Until Hormuz Fully Reopens -- Market Talk

25 may 2026, 14:15 UTC

Charlas de Mercado

Crude Futures Retreat As U.S.-Iran Progress Toward Deal -- Market Talk

25 may 2026, 13:15 UTC

Charlas de Mercado

Global Commodities Roundup: Market Talk

25 may 2026, 12:58 UTC

Charlas de Mercado

Over 60% of Albertans Indicate No Interest in Separation From Canada -- Market Talk

25 may 2026, 12:56 UTC

Charlas de Mercado

Ganancias

Canadian Earnings Lifted by Higher Commodity Prices in Latest Quarter -- Market Talk

25 may 2026, 12:48 UTC

Charlas de Mercado

Interest-Rate Cuts Unlikely in 2026 Even if Middle East Conflict Ends -- Market Talk

25 may 2026, 12:48 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

25 may 2026, 12:34 UTC

Charlas de Mercado

Dollar Extends Falls on U.S.-Iran Deal Prospects -- Market Talk

25 may 2026, 12:10 UTC

Charlas de Mercado

Adquisiciones, fusiones, absorciones

Delivery Hero's Assets Look Strategic -- Market Talk

25 may 2026, 11:00 UTC

Charlas de Mercado

Euro, Sterling, Riskier Currencies Rise Versus Weaker Dollar -- Market Talk

25 may 2026, 10:19 UTC

Charlas de Mercado

Swiss Franc Rises to Highest in More Than Two Months Vs Euro -- Market Talk

25 may 2026, 10:05 UTC

Ganancias

Tenaga Nasional: Well-Positioned to Navigate Global Geopolitical Uncertainties

25 may 2026, 10:04 UTC

Ganancias

Tenaga Nasional: Operational Performance to Remain Resilient in 2026

25 may 2026, 10:03 UTC

Ganancias

Tenaga Nasional: 1Q Operating Profit Rose on Higher Electricity Demand, Lower Fuel Prices

25 may 2026, 10:02 UTC

Ganancias

Tenaga Nasional: 1Q Rev Rose on Higher Electricity Sales

25 may 2026, 10:01 UTC

Ganancias

Tenaga Nasional 1Q Net Up 3.7% on Year

25 may 2026, 10:00 UTC

Ganancias

Tenaga Nasional 1Q Rev Up 6.6% on Year

25 may 2026, 09:56 UTC

Ganancias

Tenaga Nasional Malaysia 1st-Quarter 2026 Earnings Summary Table

25 may 2026, 09:56 UTC

Ganancias

Tenaga Nasional 1Q EPS MYR0.1883

25 may 2026, 09:56 UTC

Ganancias

Tenaga Nasional 1Q Rev MYR17.1B

25 may 2026, 09:56 UTC

Ganancias

Tenaga Nasional 1Q Net MYR1.1B

25 may 2026, 09:38 UTC

Charlas de Mercado

U.S.-Iran Talks Lifted Sentiment But No Agreement Would Quickly Restore Normal Market Conditions -- Market Talk

25 may 2026, 09:33 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

25 may 2026, 09:33 UTC

Charlas de Mercado

India's Gold Import Tax Raise Won't Curb Demand -- Market Talk

25 may 2026, 08:55 UTC

Charlas de Mercado

European Energy Stocks Slide on Falling Oil Prices -- Market Talk

Comparación entre iguales

Cambio de precio

Rhythm Pharmaceuticals Inc previsión

Precio Objetivo

By TipRanks

55.7% repunte

Estimación a 12 Meses

Media 136.77 USD 55.7%

Máximo 158 USD

Mínimo 105 USD

De acuerdo con 14 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Rhythm Pharmaceuticals Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

14 ratings

Comprar

Mantener

Vender

De acuerdo con 14 analistas que ofrecen calificaciones bursátiles a para Rhythm Pharmaceuticals Inc Dist en los últimos 3 meses.

Sentimiento

By Acuity

159 / 345 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; joint research collaboration with Axovia Therapeutics for developing in bardet-biedl syndrome; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.